News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
278,377 Results
Type
Article (14494)
Company Profile (82)
Press Release (263799)
Multimedia
Podcasts (72)
Webinars (14)
Section
Business (88408)
Career Advice (470)
Deals (15450)
Drug Delivery (83)
Drug Development (36788)
Employer Resources (50)
FDA (6418)
Job Trends (6261)
News (150964)
Policy (14141)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (456)
Accelerated approval (25)
ADA (10)
Adcomms (9)
Allergies (99)
Alliances (23332)
ALS (74)
Alzheimer's disease (527)
Antibody-drug conjugate (ADC) (168)
Approvals (6744)
Artificial intelligence (279)
ASCO (113)
Autoimmune disease (80)
Automation (22)
Bankruptcy (152)
Best Places to Work (4381)
BIO (21)
BIOSECURE Act (9)
Biosimilars (156)
Biotechnology (34)
Bladder cancer (51)
Brain cancer (41)
Breast cancer (212)
Cancer (1753)
Cardiovascular disease (202)
Career advice (423)
Career pathing (15)
CAR-T (67)
CDC (7)
Cell therapy (202)
Cervical cancer (20)
Clinical research (32650)
Collaboration (964)
Commercialization (1)
Company closure (1)
Compensation (402)
Complete response letters (47)
COVID-19 (786)
CRISPR (56)
C-suite (659)
Cystic fibrosis (62)
Data (2567)
Decentralized trials (1)
Denatured (19)
Depression (62)
Dermatology (16)
Diabetes (167)
Diagnostics (1459)
Digital health (17)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (168)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (103)
Earnings (34238)
Editorial (25)
Employer branding (4)
Employer resources (46)
Events (39959)
Executive appointments (622)
FDA (7853)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (559)
Gene editing (88)
Generative AI (28)
Gene therapy (203)
GLP-1 (497)
Government (1432)
Grass and pollen (4)
Guidances (174)
Healthcare (3641)
Hematology (66)
HIV (18)
Huntington's disease (12)
IgA nephropathy (53)
Immunology and inflammation (85)
Immuno-oncology (31)
Indications (102)
Infectious disease (885)
Inflammatory bowel disease (88)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (141)
Interviews (60)
IPO (5930)
IRA (33)
Job creations (2060)
Job search strategy (375)
JPM (29)
Kidney cancer (12)
Labor market (38)
Layoffs (211)
Leadership (10)
Legal (3450)
Liver cancer (26)
Longevity (10)
Lung cancer (237)
Lymphoma (163)
Machine learning (16)
Management (17)
Manufacturing (581)
Marketing (1)
MASH (91)
Medical affairs (1)
Medical device (1313)
Medtech (1330)
Mergers & acquisitions (10054)
Metabolic disorders (574)
mRNA (64)
Multiple sclerosis (60)
NASH (15)
Neurodegenerative disease (113)
Neuropsychiatric disorders (49)
Neuroscience (1073)
Neurotech (1)
NextGen: Class of 2026 (1589)
Non-profit (609)
Now hiring (27)
Obesity (294)
Opinion (153)
Ovarian cancer (66)
Pain (136)
Pancreatic cancer (74)
Parkinson's disease (113)
Partnered (12)
Patents (287)
Patient recruitment (188)
Peanut (15)
People (30288)
Pharmaceutical (48)
Pharmacy benefit managers (19)
Phase 1 (8457)
Phase 2 (13791)
Phase 3 (12456)
Pipeline (3591)
Policy (150)
Postmarket research (1403)
Preclinical (3411)
Press Release (25)
Prostate cancer (114)
Psychedelics (23)
Radiopharmaceuticals (162)
Rare diseases (490)
Real estate (2670)
Recruiting (19)
Regulatory (11443)
Reports (16)
Research institute (583)
Resumes & cover letters (56)
Rett syndrome (12)
RNA editing (9)
RSV (25)
Schizophrenia (87)
Series A (115)
Series B (66)
Service/supplier (2)
Sickle cell disease (57)
Special edition (11)
Spinal muscular atrophy (85)
Sponsored (11)
Startups (1656)
State (2)
Stomach cancer (6)
Supply chain (65)
Tariffs (71)
The Weekly (51)
Vaccines (276)
Venture capital (42)
Weight loss (174)
Women's health (50)
Worklife (4)
Date
Today (53)
Last 7 days (174)
Last 30 days (826)
Last 365 days (10357)
2026 (5489)
2025 (10716)
2024 (12484)
2023 (14250)
2022 (19568)
2021 (20079)
2020 (19037)
2019 (14890)
2018 (11714)
2017 (13888)
2016 (13130)
2015 (15474)
2014 (12419)
2013 (10592)
2012 (11397)
2011 (11923)
2010 (10889)
Location
Africa (323)
Alabama (20)
Alaska (1)
Arizona (88)
Arkansas (4)
Asia (21285)
Australia (2744)
California (3979)
Canada (1815)
China (761)
Colorado (177)
Connecticut (158)
Delaware (170)
Europe (41721)
Florida (759)
Georgia (76)
Hawaii (1)
Idaho (11)
Illinois (467)
India (69)
Indiana (312)
Iowa (2)
Japan (358)
Kansas (84)
Kentucky (21)
Louisiana (7)
Maine (2)
Maryland (505)
Massachusetts (3216)
Michigan (55)
Minnesota (207)
Mississippi (1)
Missouri (39)
Montana (9)
Nebraska (8)
Nevada (19)
New Hampshire (9)
New Jersey (1768)
New Mexico (7)
New York (1144)
North Carolina (748)
North Dakota (2)
Northern California (1882)
Ohio (95)
Oklahoma (5)
Oregon (18)
Pennsylvania (861)
Puerto Rico (18)
Rhode Island (18)
South America (508)
South Carolina (11)
Southern California (1754)
Tennessee (71)
Texas (565)
United States (15774)
Utah (76)
Vermont (1)
Virginia (212)
Washington D.C. (44)
Washington State (290)
West Virginia (1)
Wisconsin (51)
Wyoming (1)
278,377 Results for "recursion pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Patient advocate offers Recursion a powerful reason to keep going in rare disease
Staff at Salt Lake City-based techbio company Recursion recently heard from Jenny and Tim Jones about their challenging family history of familial adenomatous polyposis.
April 29, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
Recursion Reports First Quarter Financial Results and Provides Business Update
May 6, 2026
·
18 min read
Layoffs
Recursion Downsizes by 20% To Boost Cash Position
As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027.
June 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
·
22 min read
Startups
Altitude Labs serves up higher education for biotech founders
Altitude Labs, an offshoot of AI-focused techbio Recursion, is teaching scientists to build companies, one founder at a time.
April 29, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
July 9, 2025
·
5 min read
Press Releases
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
·
15 min read
Press Releases
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
·
16 min read
Biotech Bay
Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
Helix, a leading population genomics company and provider of precision medicine genomics solutions, announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals, a leading clinical-stage TechBio company decoding biology to industrialize drug discovery.
June 24, 2024
·
2 min read
Neuroscience
Recursion Reports Thin Mid-Stage Efficacy Data for Rare Brain Disease Therapy
Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine the need for an additional study.
September 4, 2024
·
2 min read
·
Tristan Manalac
1 of 27,838
Next
